Voriconazole

Histoplasmosis, Candidemia, Coccidioidomycosis + 24 more

Treatment

13 FDA approvals

20 Active Studies for Voriconazole

What is Voriconazole

Voriconazole

The Generic name of this drug

Treatment Summary

Voriconazole is an antifungal medication used to treat serious fungal infections in immunocompromised people. It is used to treat invasive candidiasis, invasive aspergillosis, and other emerging fungal infections. Voriconazole is also effective against some fungi that are resistant to other antifungal medications. It was approved by the FDA in 2002 under the trade name Vfend.

Voriconazole

is the brand name

image of different drug pills on a surface

Voriconazole Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Voriconazole

Voriconazole

2002

85

Approved as Treatment by the FDA

Voriconazole, also known as Voriconazole, is approved by the FDA for 13 uses like Esophageal Candidiasis and Scedosporium Infection .

Esophageal Candidiasis

Scedosporium Infection

Systemic candidiasis

refractory Fungal Infections

Invasive Aspergillosis

Hematopoietic stem cells

Neutropenia

Neuroaspergillosis

Candida (fungus)

prophylaxis of moderate Pneumocystis pneumonia

Candidemia

Fusariosis

Mycoses

Effectiveness

How Voriconazole Affects Patients

Voriconazole is a medication used to stop fungus from growing. It can cause liver and sun sensitivity issues in some people.

How Voriconazole works in the body

Voriconazole is a medication used to treat fungal infections caused by organisms such as _Aspergillus spp._ and _Candida spp_. Voriconazole works by blocking a key enzyme called 14-alpha sterol demethylase. This enzyme is necessary for fungi to produce a type of fat called ergosterol, which is essential for cell membrane function. By blocking the production of ergosterol, voriconazole limits fungal cell growth and allows the body's immune system to clear the infection.

When to interrupt dosage

The proposed dosage of Voriconazole is contingent upon the diagnosed condition, including Esophageal Candidiasis, Meningitis, Fungal and Immunosuppression. The degree of measure varies as per the procedure of delivery (e.g. Tablet or Oral) outlined in the table below.

Condition

Dosage

Administration

talaromycosis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Aspergillosis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Meningitis, Fungal

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Aspergillosis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

prophylaxis of moderate Pneumocystis pneumonia

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Peritonitis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Debridement

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Lung Transplant

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Hematopoietic stem cells

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Candidemia

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Fusariosis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Aspergillosis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Histoplasmosis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Coccidioidomycosis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Neutropenia

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Immunosuppression

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Esophageal Candidiasis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Yeast Infection

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Candida (fungus)

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

aspergillus endophthalmitis

10.0 mg/mL, , 50.0 mg, 200.0 mg, 40.0 mg/mL, 200.0 mg/mL

, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Intravenous, Oral, Tablet, film coated, Tablet, film coated - Oral, Suspension, Suspension - Oral, Powder, for suspension - Oral, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Tablet - Oral, Powder - Intravenous, Tablet, film coated - Nasal, Nasal, Powder, for suspension, Tablet, Powder, for solution, Powder, for solution - Intravenous, Tablet, coated - Oral, Tablet, coated, Powder

Warnings

Voriconazole Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Voriconazole may interact with Pulse Frequency

There are 20 known major drug interactions with Voriconazole.

Common Voriconazole Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Voriconazole.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Voriconazole.

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be decreased when combined with Voriconazole.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Voriconazole.

5-androstenedione

Major

The metabolism of 5-androstenedione can be decreased when combined with Voriconazole.

Voriconazole Toxicity & Overdose Risk

Overdosing on Voriconazole can cause sensitivity to light and a lengthened QT interval. If someone overdoses, it is recommended to provide supportive care and monitor their heart activity. Activated charcoal can help remove unabsorbed drug from the body, and hemodialysis can be used to remove absorbed drug at a rate of 121 mL/min. Studies have found that taking high doses of Voriconazole can lead to liver cancer in rats and mice.

image of a doctor in a lab doing drug, clinical research

Voriconazole Novel Uses: Which Conditions Have a Clinical Trial Featuring Voriconazole?

31 active clinical trials are currently underway to investigate the potential of Voriconazole to address Aspergillosis, Aspergillosis and Penicillium marneffei infection.

Condition

Clinical Trials

Trial Phases

talaromycosis

1 Actively Recruiting

Phase 3

Esophageal Candidiasis

0 Actively Recruiting

Osteomyelitis

0 Actively Recruiting

Fusariosis

0 Actively Recruiting

Neutropenia

3 Actively Recruiting

Phase 2, Phase 3

Immunosuppression

9 Actively Recruiting

Phase 2, Phase 4, Not Applicable, Phase 3, Early Phase 1

Aspergillosis

0 Actively Recruiting

Candida (fungus)

0 Actively Recruiting

Histoplasmosis

2 Actively Recruiting

Phase 3, Phase 2

Mycoses

0 Actively Recruiting

Aspergillosis

0 Actively Recruiting

Neuroaspergillosis

0 Actively Recruiting

refractory Oral Candidiasis

0 Actively Recruiting

Lung Transplant

17 Actively Recruiting

Not Applicable, Phase 2, Phase 3, Phase 1

Candidemia

1 Actively Recruiting

Phase 3

Peritonitis

0 Actively Recruiting

Meningitis, Fungal

0 Actively Recruiting

Debridement

0 Actively Recruiting

Yeast Infection

0 Actively Recruiting

Valve Replacement

0 Actively Recruiting

Voriconazole Reviews: What are patients saying about Voriconazole?

5

Patient Review

10/29/2014

Voriconazole for Aggressive Fungal Infection - Invasive Aspergillosis

I'm very photosensitive, so this summer I made sure to get a good tan. Even with that protection, I still can't seem to get my dosage high enough to where it's therapeutic. I'm also working on shrinking a fungal infection in my lungs.

5

Patient Review

4/2/2019

Voriconazole for A Fungal Infection - Aspergillosis

Voriconazole has been a lifesaver for me. I'm 60 now and it's kept the fungal infection at bay for years. Recently, I've also started to get skin cancer on my face and ears. So, during the summer months, I have to make sure to wear a wide-brimmed hat when I go outside.

4.7

Patient Review

12/20/2011

Voriconazole for Aggressive Fungal Infection - Invasive Aspergillosis

I saw significant improvements in my asthma symptoms after just one week of using this medication. I was struggling for two years before they found the root cause (fungus in my lungs) but now I feel like a normal person again.

3

Patient Review

11/11/2022

Voriconazole for Fungal Infection of the Esophagus

I used this treatment for thirteen days to treat a stubborn candida infection. I lost half of my hair during that time, and I'm still losing it one month later. There were also some vision-related side effects, but they're gone now. The candida symptoms returned two days after stopping the treatment. Although the vaginal yeast feels a little bit better, it's still painful and tests positive.

2.7

Patient Review

5/4/2012

Voriconazole for Aggressive Fungal Infection - Invasive Aspergillosis

V-fend has been successful in treating my ABPA, but I have developed more severe allergic reactions each time. This last reaction could have been fatal if I hadn't stopped taking the medication.

2.3

Patient Review

9/18/2010

Voriconazole for Aggressive Fungal Infection - Invasive Aspergillosis

I had some really intense hallucinations while on this medication. I was also extremely irritable and saw things that weren't actually there. It was a scary experience for both me and the people around me.

2.3

Patient Review

2/5/2012

Voriconazole for Aggressive Fungal Infection - Invasive Aspergillosis

I have been having severe gastrointestinal issues since taking this medication. My joints and muscles hurt, and now my face, throat, and stomach are swelling severely . I look like I've gained a lot of weight in a short amount of time.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about voriconazole

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is voriconazole an antibiotic?

"Voriconazole is used to treat fungal infections. It stops the growth of fungi."

Answered by AI

How long do you take voriconazole?

"The length of time that you will have to take Vfend (voriconazole) will vary depending on the severity of your infection. Some people may need to take this medication for several months."

Answered by AI

Which is better fluconazole or voriconazole?

"At the end of the study, the researchers found that voriconazole was just as good as fluconazole at treating esophageal candidiasis."

Answered by AI

What are the side effects of voriconazole?

"The most commonly reported side effects of voriconazole are blurred vision, changes in vision color, visual disturbance, and enhanced visual perception. Other side effects include fever, nausea, skin rash, vomiting, and chills."

Answered by AI

Clinical Trials for Voriconazole

Image of Mayo Clinic in Phoenix, United States.

Oteseconazole for Fungal Infections

18+
All Sexes
Phoenix, AZ

This Phase II platform trial will evaluate the safety, tolerability, and effectiveness of investigational antifungal agents as salvage or consolidation therapy in adults with dimorphic fungal infections, including coccidioidomycosis, blastomycosis, and histoplasmosis. The study will enroll adults who are receiving active antifungal therapy and who have intolerance, failure, or unavailability of standard first-line consolidation therapy. The first investigational agent evaluated in the platform trial is oteseconazole. Participants will receive study drug and complete follow-up assessments for symptom status, functional status, adverse events, laboratory safety, study drug discontinuation, and quality of life. Participants will be followed during therapy and for up to 6 months after therapy.

Phase 2
Waitlist Available

Mayo Clinic (+3 Sites)

Matthew Pullen, MD

Image of University of Minnesota in Minneapolis, United States.

LAmB and Posaconazole for Histoplasmosis

18+
All Sexes
Minneapolis, MN

The purpose of the study is threefold: 1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to severe histoplasmosis. 2. Assess the safety and efficacy of oral posaconazole 300mg delayed-release tablets three times daily for two days then once daily for consolidation therapy compared to SOC oral itraconazole 200 mg capsules three times daily for three days then twice daily in moderate to severe histoplasmosis 3. Assess the safety and efficacy of 6 months of consolidation therapy compared to the SOC 12 months of consolidation therapy in persons with HIV on appropriate antiretroviral therapy.

Phase 3
Waitlist Available

University of Minnesota

Nathan Bahr, MD

Image of University of Alberta in Edmonton, Canada.

Fibroscan-Guided Immunosuppression Reduction for Post-Transplant Care

18+
All Sexes
Edmonton, Canada

Following Liver transplantation, recipients remain on life long immunosuppression. Prolonged exposure to immunosuppression is associated with side effects and complications including kidney dysfunction, diabetes, heart disease and cancer risk. Therefore studies are looking at safe ways to reduce or stop immunosuppression. An individual without autoimmune liver disease (these patients are at higher risk of rejection), without history of rejection, with normal blood tests (liver biochemistry, liver function, etc.) can be eligible for minimization of immunosuppression. A recent study showed use of fibroscan (an Ultrasound, which provides information on liver stiffness (diseased liver is hard while a normal liver is soft) and fat content) provides more objective information to help investigators select individuals who will tolerate immunosuppression minimization. Our goal is to see if use of fibroscan allows the investigators to safely minimize immunosuppression in eligible individuals. The secondary aims are to assess benefit on kidney function, heart disease and risk factors for heart disease.

Recruiting
Has No Placebo

University of Alberta

Have you considered Voriconazole clinical trials?

We made a collection of clinical trials featuring Voriconazole, we think they might fit your search criteria.
Go to Trials
Image of Johns Hopkins University School of Medicine in Baltimore, United States.

Fostamatinib for Lung Transplant Rejection

18 - 99
All Sexes
Baltimore, MD

Background: People who have lung transplants often survive 6 or 7 years. But some people develop donor-specific antibodies (DSA) after their transplants; antibodies are proteins that attack foreign invaders in the body. Antibodies typically kill viruses and other agents that can cause disease. But when the antibodies attack a transplanted organ, they can cause the body to reject the new tissues. People who develop DSA after a transplant have a higher risk of death within 1 year. Objective: To test a drug called fostamatinib in people who develop DSA after a lung transplant. Eligibility: Adults aged 18 and older who developed DSA after a lung transplant. Design: Participants will continue with their standard care after a transplant. Fostamatinib is a pill taken by mouth. Some participants will take the study drug along with their standard care; others will take a placebo. A placebo is a pill that looks just like the real drug but contains no medicine. All participants will take 1 pill per day for 2 weeks. Then they will take 2 pills per day for the next 6 weeks. Participants will have clinic visits every 2 weeks while taking their pills. They will have a physical exam, with blood and urine tests, during each visit. If participants have fluid samples collected from their airways during their standard treatment, some extra fluid may be collected for this study. Participants will have a follow-up visit 4 weeks after they stop taking their pills.

Phase 1
Recruiting

Johns Hopkins University School of Medicine (+4 Sites)

Sean T Agbor-Enoh, M.D.

Image of University of California, San Francisco in San Francisco, United States.

Maraviroc for Primary Graft Dysfunction

18+
All Sexes
San Francisco, CA

Lung transplant recipient survival lags other solid organ recipients, with the main early cause of death being primary graft dysfunction (PGD). PGD occurs in up to 1/3 of all recipients, is driven by the body's innate immune response, and has no known medical therapies for treatment or prevention. Investigators have recently shown that Natural Killer (NK) cells, a key innate immune cell, are critical in causing PGD. Importantly, the investigators found that Maraviroc, an FDA-approved drug that works to inhibit these immune cells, prevented lung injury in mouse models of PGD. The goal of this clinical trial is to learn if Maraviroc works to treat PGD in Lung Transplant patients who are above the age of 18 and have a PGD risk score greater than 50%. The objectives the study hopes to address are: To address the safety and tolerability of Maraviroc. To test a strategy for PGD enrichment in a lung transplant population. To measure the efficacy and biological efficacy of using Maraviroc. To study the biochemical, physiologic, and molecular effects of the drug on the body. This will be a double blind study where patients will either get the Maraviroc drug or a placebo. Researchers will then compare the two groups to address the above objectives. Participants will: Take drug Maraviroc or a placebo every 12 hours for 3 days post surgery. Follow up will occur during the entire length of stay at UCSF, about 16 days, with a single 12 month follow up once released.

Phase 2
Recruiting

University of California, San Francisco

Daniel Calabrese, MD

Image of Kidney Transplant Research in Vancouver, Canada.

Immunosuppressants for Kidney Transplant

18+
All Sexes
Vancouver, Canada

Kidney transplant is often the best treatment for people with kidney failure, but transplanted kidneys don't always last a lifetime. Many transplanted kidneys fail within 12 years, leaving patients needing dialysis or another transplant. One major issue is something called "allosensitization," which happens when the immune system attacks the donated kidney due to foreign markers on the kidney. This makes it harder to match a patient with another donor kidney in the future. To try to prevent this, patients are given immunosuppressants (drugs that weaken the immune system) after a transplant to stop the immune system from attacking the new kidney. However, after a kidney transplant fails and patients return to dialysis, there's no clear evidence that continuing immunosuppressants helps prevent allosensitization. Plus, these drugs have serious risks, including infections, heart disease, and even cancer. The PART study is a pilot study designed to explore whether continuing immunosuppression after a failed transplant for two years (instead of stopping after six months) can lower the risk of allosensitization and whether it is safe to do so. This pilot will also gather data that will be used for a larger trial in the future. The study will be done at 12 different research centers, and around 96 patients will be enrolled in the pilot trial. The ultimate goal is to better understand if continuing immunosuppressants after transplant failure can make a difference, and whether it's safe enough to proceed to a larger, more definitive trial.

Waitlist Available
Has No Placebo

Kidney Transplant Research

Have you considered Voriconazole clinical trials?

We made a collection of clinical trials featuring Voriconazole, we think they might fit your search criteria.
Go to Trials
Image of Duke University Medical Center in Durham, United States.

Liposomal Amphotericin B + Flucytosine for Fungal Infection

18+
All Sexes
Durham, NC

LAmB-FAST is a factorial randomized controlled trial simultaneously testing two interventions in one trial. LAmB-FAST seeks to inform treatment guidelines on the induction and maintenance therapy of HIV-associated talaromycosis (formerly called penicilliosis) and will answer the following three questions: 1. Is induction therapy using a single 10 mg\\/kg dose of liposomal amphotericin B (LAmB) is more effective than 14 days of the conventional deoxycholate amphotericin B (DAmB)? 2. Is adding flucytosine (5FC) to amphotericin B more effective than amphotericin B alone? 3. Is HIV viral load guided stopping of itraconazole maintenance therapy as effective as the current CD4 guided strategy in the prevention of talaromycosis relapse?

Phase 3
Waitlist Available

Duke University Medical Center

Thuy Le, MD, PhD

Viatris Inc.

Image of University of California, Los Angeles (Site #: 71123) in Los Angeles, United States.

Belumosudil for Lung Transplant

Any Age
All Sexes
Los Angeles, CA

The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication, will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy that shows evidence of rejection or inflammation to the transplanted lung(s). For this study, biopsies that show evidence of Acute Rejection (AR), Lymphocytic Bronchiolitis (LB), Organizing Pneumonia (OP) or Acute Lung Injury (ALI) are referred to as "Qualifying Biopsies"; patients who had evidence of one or more of these conditions on a recent biopsy are eligible for enrollment in this study. Belumosudil is an investigational drug that blocks a molecule in the body that reduces inflammation and scarring and may play a role in the development and progression of CLAD. Belumosudil is a drug approved by the FDA to treat adults and children 12 years and older with chronic graft-versus-host disease (cGVHD), a condition with some similarities to CLAD. The primary objective it to determine the efficacy of treatment with Belumosudil + maintenance immunosuppression (IS) versus placebo + maintenance IS on preventing the subsequent development of probable or definite CLAD, lung retransplant, or death.

Phase 2
Recruiting

University of California, Los Angeles (Site #: 71123) (+14 Sites)

Scott M. Palmer, M.D., M.H.S.

Have you considered Voriconazole clinical trials?

We made a collection of clinical trials featuring Voriconazole, we think they might fit your search criteria.
Go to Trials